| 0 (0%) | 10-15 12:13 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.29  |
1-year : | 2.46 |
| Resists | First : | 1.96 |
Second : | 2.1 |
| Pivot price | 1.88 |
|||
| Supports | First : | 1.74 | Second : | 1.44 |
| MAs | MA(5) : | 1.88 |
MA(20) : | 1.88 |
| MA(100) : | 1.68 |
MA(250) : | 1.96 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 40.7 |
D(3) : | 42 |
| RSI | RSI(14): 48.9 |
|||
| 52-week | High : | 5.17 | Low : | 1.04 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ACRS ] has closed above bottom band by 37.9%. Bollinger Bands are 44.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.89 - 1.9 | 1.9 - 1.91 |
| Low: | 1.72 - 1.73 | 1.73 - 1.74 |
| Close: | 1.8 - 1.81 | 1.81 - 1.82 |
Wed, 15 Oct 2025
How ACRS stock compares to market leaders - 2025 Geopolitical Influence & Consistent Growth Equity Picks - newser.com
Tue, 14 Oct 2025
ACRS stock outlook for YEAR - 2025 Retail Activity & AI Driven Price Forecasts - newser.com
Sun, 12 Oct 2025
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth? - Yahoo Finance
Thu, 09 Oct 2025
Annual ACRS gala - Northwest Asian Weekly
Tue, 30 Sep 2025
Major Immuno-Inflammatory Pipeline Updates: Aclaris R&D Day to Showcase Novel Kinase Inhibitor Progress - Stock Titan
Tue, 23 Sep 2025
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $8.71 Consensus Price Target from Analysts - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 108 (M) |
| Shares Float | 73 (M) |
| Held by Insiders | 2.6 (%) |
| Held by Institutions | 85.9 (%) |
| Shares Short | 5,550 (K) |
| Shares Short P.Month | 5,920 (K) |
| EPS | -1.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.22 |
| Profit Margin | 0 % |
| Operating Margin | -951.5 % |
| Return on Assets (ttm) | -20.9 % |
| Return on Equity (ttm) | -101.5 % |
| Qtrly Rev. Growth | -35.8 % |
| Gross Profit (p.s.) | -0.34 |
| Sales Per Share | 0.15 |
| EBITDA (p.s.) | -0.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -47 (M) |
| PE Ratio | -1.19 |
| PEG Ratio | 0 |
| Price to Book value | 1.52 |
| Price to Sales | 12.03 |
| Price to Cash Flow | -20.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|